Reporting owner · CIK 0001388325
Novo Holdings A/S
SEC Form 4 history across 2 companies, 12 transactions and 2 filings.
10%Hemab Therapeutics Holdings, Inc.
Open-market transaction mix100% buys1 buys · 0 sales
Available history · May 01, 2026 – May 04, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
COAGHemab Therapeutics Holdings, Inc. | Novo Holdings A/S10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
COAGHemab Therapeutics Holdings, Inc. | Novo Holdings A/S10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
COAGHemab Therapeutics Holdings, Inc. | Novo Holdings A/S10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
COAGHemab Therapeutics Holdings, Inc. | Novo Holdings A/S10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
COAGHemab Therapeutics Holdings, Inc. | Novo Holdings A/S10% | C · unknownSEC filing ↗ | UnknownView disclosure → | |
AVLNAvalyn Pharma Inc. | Novo Holdings A/S10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
AVLNAvalyn Pharma Inc. | Novo Holdings A/S10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
AVLNAvalyn Pharma Inc. | Novo Holdings A/S10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
AVLNAvalyn Pharma Inc. | Novo Holdings A/S10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
AVLNAvalyn Pharma Inc. | Novo Holdings A/S10% | C · unknownDerivative securitySEC filing ↗ | $0View disclosure → | |
AVLNAvalyn Pharma Inc. | Novo Holdings A/S10% | P · buySEC filing ↗ | $9.99MView disclosure → | |
AVLNAvalyn Pharma Inc. | Novo Holdings A/S10% | C · unknownSEC filing ↗ | UnknownView disclosure → |
Latest Form 4 facts
Quick context from source filings
Latest open-market transaction
buy at Avalyn Pharma Inc. on May 01, 2026 valued at $9,999,990.
Review SEC filingLatest sale
No open-market insider sale is available.
Monthly open-market activity
Last 1 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| May 2026 | 1 | 0 | $9,999,990.00 | $0.00 | $9,999,990.00 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Average P/S size$10M
Median P/S size$10M
Direct12
Indirect0
May 04, 2026unknown
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
1 observations · May 4, 2026 – May 4, 2026. Window ends at the latest available report, not today.
Selected observation · May 4, 20264,180,550 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| May 4, 2026 | 4,180,550 | May 6, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Novo Holdings A/S Insider Activity FAQ
SEC Form 4 context
Who is Novo Holdings A/S?
Novo Holdings A/S is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001388325.
Which companies has Novo Holdings A/S reported transactions for?
Hemab Therapeutics Holdings, Inc., Avalyn Pharma Inc.
When was Novo Holdings A/S's latest insider buy?
buy at Avalyn Pharma Inc. on May 01, 2026 valued at $9,999,990.
When was Novo Holdings A/S's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.